Changes to This Summary (09/25/2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text to state that not all analgesic agents have been shown to provide clinical benefit when used in conjunction with opioids; a dose escalation, double-blind, randomized placebo-controlled phase III trial of ketamine in patients with uncontrolled pain on opioids versus placebo reported no difference in pain response between arms and almost twice the incidence of adverse effects in the ketamine group as in the placebo arm (cited Hardy et al. as reference 207).
This summary is written and maintained by the PDQ Supportive and Palliative Care Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.